Purpose: This literature-based review explores the multifaceted impact of Parkinson’s disease (PD) on patients’ quality of life, with particular emphasis on non-motor symptoms. Building upon the findings of Karlsen et al., the article integrates contemporary evidence to highlight the role of chronic pain, sleep disturbances, fatigue, depression, emotional dysfunction, and social isolation in shaping patient well-being. Methods: The review centers on the prospective study conducted by Karlsen et al. (1993–1997), which used the Nottingham Health Profile (NHP) to assess health-related quality of life in 111 patients with PD. Supplementary sources from recent decades, were analysed to provide an updated perspective on non-motor symptom prevalence, clinical relevance, and management strategies. These sources include data on physical activity, emotional health, digital health tools, and interdisciplinary care models. Results: Non-motor symptoms frequently have a more significant negative impact on daily functioning and subjective quality of life than motor symptoms. These include not only chronic pain and sleep disturbances but also persistent fatigue, mood disorders, social disengagement, and reduced physical activity. Despite their prevalence, non-motor symptoms remain underrecognized and undertreated in clinical practice. Conclusions: A holistic, multidisciplinary approach is essential for improving quality of life in patients with PD. Effective management should combine pharmacological therapies with psychological support, physical rehabilitation, group-based interventions, and the use of wearable technologies. Future research should prioritize the development of integrated care models, the use of disease-specific quality-of-life assessment tools, and targeted strategies for fatigue, depression, and endocrine comorbidities such as hypothyroidism.

Background: Myocardial fibrosis (MF) is a dynamic remodeling process characterized by excessive extracellular matrix (ECM) deposition, fibroblast activation, and dysregulated matrix turnover. Although initially reparative, persistent fibrotic remodeling promotes myocardial stiffening, electrical instability, and progressive cardiac dysfunction across diverse cardiovascular diseases. Circulating biomarkers reflecting collagen synthesis, degradation, proteolytic regulation, and inflammatory activation have emerged as potential tools for assessing fibrotic activity and risk stratification. Methods: This targeted narrative review was based on manually guided searches of PubMed and Scopus, supplemented by citation chaining and inclusion of landmark mechanistic and translational studies. Publications addressing myocardial extracellular matrix remodeling, circulating fibrosis-related biomarkers and imaging-derived fibrosis phenotypes were selected for qualitative synthesis. Results: Myocardial fibrosis reflects interconnected inflammatory, neurohormonal, oxidative, and extracellular matrix remodeling pathways. Among circulating biomarkers, C-terminal propeptide of procollagen type I (PICP) showed the most consistent association with myocardial collagen burden and adverse outcomes, whereas carboxy-terminal telopeptide of type I collagen (CITP), matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs), galectin-3, osteopontin, soluble suppression of tumorigenicity 2 (sST2), and natriuretic peptides provided more context-dependent signals. Standalone interpretation remains limited by restricted cardiac specificity, renal dysfunction, systemic inflammation, assay heterogeneity, and lack of standardized thresholds. Integration with cardiac magnetic resonance (CMR)-derived late gadolinium enhancement (LGE), T1 mapping, and extracellular volume (ECV) may improve biological and structural phenotyping. Conclusions: Circulating biomarkers capture complementary dimensions of myocardial remodeling but cannot replace structural imaging. We propose an updated, hypothesis-generating biomarker–imaging framework integrating inflammatory activation, collagen turnover, matrix quality, hemodynamic stress, and structural imaging to support phenotypic stratification and future validation of antifibrotic strategies.

Psoriasis, a chronic inflammatory skin disease, poses challenges not only due to its somatic symptoms but also because of its significant impact on patients’ quality of life, mental health, and social and occupational functioning. This review aimed to analyze the multidimensional influence of psoriasis on patients’ psychosocial condition, with particular attention to stigmatization, symptoms of depression and anxiety, suicide risk, and factors affecting quality of life. The analysis is based on up-to-date literature from systematic reviews, cross-sectional and qualitative studies published between 2010 and 2025. Findings indicate that patients with psoriasis are significantly more likely to experience depressive and anxiety disorders, often regardless of lesion severity. Subjective factors such as body image perception, social stigma, loss of control over one’s body, and limitations in professional life play a crucial role. Importantly, some patients exhibit suicidal ideation at early stages of the disease, even before treatment begins. Simultaneously, evidence points to the necessity of an integrated care model that includes dermatological, psychological, and social support. Incorporating mental health and quality of life assessments into routine clinical practice can significantly improve treatment outcomes and patient well-being. This review emphasizes the need for a holistic approach to psoriasis management that addresses not only physical but also psychological and social dimensions.

Aim: This narrative review aims to evaluate the current scientific evidence on the effectiveness of physiotherapy and physical activity in reducing pain and improving quality of life in women with endometriosis. Methods: A literature search was conducted using PubMed and Google Scholar databases to identify English-language studies published between 2013 and 2024. The search included terms such as “endometriosis”, “physiotherapy”, “exercise”, and “chronic pelvic pain”. The review included randomized controlled trials, observational studies, and clinical guidelines addressing the use of non-pharmacological interventions in endometriosis management. Results: The analysis indicates that various physiotherapeutic techniques, including pelvic floor muscle training, manual therapy, and relaxation strategies, may alleviate pain symptoms, especially in cases of superficial dyspareunia and chronic pelvic pain. Regular physical activity, such as aerobic or stretching exercises, may support hormonal balance, reduce systemic inflammation, and contribute to improved mental health. However, the available evidence is heterogeneous, and methodological limitations of existing studies hinder definitive conclusions. Conclusion: Physiotherapy and physical activity represent promising adjunctive approaches in the treatment of endometriosis, particularly for patients who experience insufficient relief from pharmacological or surgical therapies. Further high-quality, controlled studies are required to establish standardized treatment protocols and confirm the long-term effectiveness of these interventions.

Introduction: Affective disorders are serious, long-lasting, and often relapsing conditions that strike an individual unpredictably. The ideal psychiatric monitoring mechanism would predict coming episodes before their full-blown clinical symptoms develop. This would be a tremendous advance and may be possible using our current understanding of the nature of affective disorders, portable device-based data collection capabilities, and remote data analysis. There are numerous reviews of the literature that cover the symptom recognition of affective disorders using mobile devices, but there are no reviews on the actual prediction of affective episodes. This review aims to cover that gap. Methods: A systematic review of five databases (2016-2025) was conducted and included 10 observational studies, mostly designed as prospective cohorts, that concentrated on the prognosis of affective disorders and utilized wearable devices. The variables under study were circadian parameters, sleep metrics, amounts and intensity of physical activity, and light exposure. Although the methodological diversity among the studies made direct comparisons problematic, the studies allowed for the identification of certain findings that appear promising for predicting the occurrence of affective episodes. Results: The review encompassed 10 observational studies (1416 subjects). Our synthesis showed that it is possible, even feasible, to predict affective episodes using mathematical models. These models assess the types of characteristic disturbances that individuals with affective disorders have in their circadian rhythms. When we applied some standard methods for doing this kind of analysis (Accuracy Metrics and AUC Values), the results gave us AUC values that ranged from about 0.67 to 0.98, depending on several factors. Conclusions: Predicting affective episodes is possible using wearable technology or smartphone app, which can detect disturbances in a person's circadian rhythm. Currently, the best methods for doing this merit a look because they could indeed allow for early intervention before the onset of manic or depressive symptoms.

In recent years, the gut microbiome has gained increasing recognition as a crucial modulator of physiological homeostasis, including cardiovascular function. Numerous studies indicate that disruptions in the composition and activity of intestinal microbiota—referred to as dysbiosis—may significantly contribute to the onset and progression of cardiovascular diseases, including atherosclerosis, hypertension, heart failure, and arrhythmias. Particular attention has been paid to microbial metabolites such as trimethylamine-N-oxide (TMAO), short-chain fatty acids (SCFAs), and lipopolysaccharides (LPS), which exert significant effects on inflammatory, immunological, and metabolic pathways. The aim of this review was to synthesize current evidence regarding the association between the gut microbiota and the pathogenesis of cardiovascular disorders, emphasizing potential molecular mechanisms and therapeutic opportunities arising from microbiome modulation. Additionally, environmental, dietary, and pharmacological factors influencing microbiota composition and their implications for cardiovascular risk were discussed. Accumulated evidence suggests the gut microbiome could serve both as a biomarker of cardiovascular risk and as a potential therapeutic target within personalized medicine frameworks. However, further clinical research is required to precisely define its role in the pathogenesis and treatment of cardiovascular diseases.